This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
April 16, 2012 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, announced today that Transcept management is scheduled to present at the BioCentury Future Leaders in the Biotech Industry Conference in
New York on
April 20, 2012 at
8:30 a.m. ET.
A live audio webcast and replay of this presentation may be accessed at
http://www.media-server.com/m/p/dnf5o64x and on the Transcept Investor webpage at
Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Intermezzo® (zolpidem tartrate) sublingual tablet C-IV is the first FDA approved Transcept product. Purdue holds commercialization and development rights for Intermezzo in
the United States. Transcept is currently conducting a Phase 2 study of an investigational product, TO-2061, in patients with obsessive-compulsive disorder. For further information about Transcept, please visit
Contact:Transcept Pharmaceuticals, Inc.
Greg MannSr. Director, Corporate Communications(510) 215-3567
SOURCE Transcept Pharmaceuticals, Inc.